The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alessa Therapeutics for its lead product ...

Enolen is currently being studied in a Phase 1 trial evaluating its safety, tolerability and preliminary efficacy for localized sustained delivery of enzalutamide into the prostate. Alessa expects to ...

Study results are based on Surveillance, Epidemiology, and End Results-Medicare data for 166,581 patients receiving surgery or radiation for localized prostate cancer.

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer IRVINE, CA – January XX, 2026 (GlobeNewswire) ...

Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post ...

New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...

CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate ...

Prostate cancer patients with metastatic disease and low-volume primary tumors appear to have a poor prognosis, according to ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...